Liraglutide and insulin glargine outperformed glimepiride and sitagliptin as single add-on agents to metformin for treating patients with type 2 diabetes in a multicenter US trial that randomized just over 5000 patients.

The GRADE trial ran for roughly 5 years at 36 US centers and was designed to answer the question of which...